In a discovery that feels, in a way, like turning back the clock on the body’s defenses, scientists at the Massachusetts Institute of Technology (MIT) say they’ve found a promising method to rejuvenate the immune system — at least in early laboratory studies. The work, published this month in Nature, shows that by reprogramming cells in the liver using messenger RNA (mRNA), it’s possible to boost T‑cell development and function in aged mice — a result that could pave the way for new treatments to help older adults better fend off infection, respond to vaccines and even improve cancer therapy outcomes.
Our immune system naturally weakens with age. One key reason is the gradual shrinkage of the thymus, the organ where T cells — crucial white blood cells that recognize and wipe out infections — are trained and matured. As the thymus involutes beginning in early adulthood, fewer new T cells are produced, leaving older individuals more vulnerable to pathogens and less responsive to vaccines.
Instead of attempting to regrow or transplant thymus tissue — a complex and potentially risky process — the MIT researchers took a different approach: they engineered the liver to act as a temporary “factory” that produces the same supportive signals the thymus normally provides. Using mRNA carried in lipid nanoparticles (similar to the technology used in some COVID‑19 vaccines), they delivered three key molecules known to promote T‑cell survival and maturation into liver cells.
When aged mice received this treatment over four weeks, the results were striking: their T‑cell populations increased in number and diversity, giving them stronger responses to experimental vaccines, and enhancing their immune system performance compared to untreated aged controls. In a further test, older mice given the mRNA therapy and a cancer immunotherapy drug designed to “take the brakes off” T cells showed better survival and tumor control than those that received the cancer drug alone.
Scientists emphasize that the liver was chosen for this role because it remains active at producing proteins even in older age, and blood from all parts of the body — including circulating T cells — flows through it, maximizing the potential impact of the secreted factors.
While the research so far has been conducted in animal models, the findings suggest a new strategy for temporarily boosting immune function by mimicking the beneficial signals lost when the thymus ages. If this approach can eventually be translated safely into humans, it could mean stronger protection against infections and better responses to vaccines for older adults, as well as improved outcomes when combining such treatments with therapies like cancer immunotherapy.
However, caution remains essential: scientists will need to test safety, dosing and long‑term effects in human studies before considering clinical use. Rejuvenating a complex system like immunity is a significant challenge, and early success in mice doesn’t always translate directly to people. Still, this study represents an exciting step toward understanding how the aging immune system might be rejuvenated in a controlled and targeted way.
AI Image Disclaimer “Visuals are created with AI tools and are intended for representation only.”
Sources MIT News Nature / SciTechDaily GenEngNews
Published by Banx Network. This article is part of the Banx decentralized media programme, powered by the BXE token on the XRP Ledger.
